Chinese biopharmaceutical company: LM-350 "CDH17 ADC" clinical trial application approved by NMPA.

China Biopharmaceuticals announced that LM-350, a first-class innovative drug developed independently by its wholly-owned subsidiary Lixin Medicine Technology Co., Ltd., has obtained clinical trial approval from the China National Medical Products Administration. LM-350 is an ADC targeting CDH17 developed based on Lixin Medicine's new generation LM-ADC platform, which has high selectivity in binding to CDH17 and strong internalization capabilities.